Meta-analysis of traditional Chinese medicine on chronic kidney disease

References

• Levey AS, Coresh J, Bolton K, et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 SUPPL. 1):S1–S266.
   PubMed Web of Science ®Google Scholar
• Romagnani P, Remuzzi G, Glassock R, et al. Chronic kidney disease. Nat Rev Dis Primers. 2017;3(1):1–24. doi: 10.1038/nrdp.2017.88
   Web of Science ®Google Scholar
• Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet. 2017;389(10075):1238–52. doi: 10.1016/S0140-6736(16)32064-5
   PubMed Web of Science ®Google Scholar
• Xie Y, Bowe B, Mokdad AH, et al. Analysis of the global burden of disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 2018;94(3):567–81. doi: 10.1016/j.kint.2018.04.011
   PubMed Web of Science ®Google Scholar
• Lv J-C, Zhang L-X. Prevalence and disease burden of chronic kidney disease. Renal Fibro Mech Therapies. 2019;1165:3–15.
   Google Scholar
• Ng JKC, Li PKT. Chronic kidney disease epidemic: how do we deal with it? Nephrology. 2018;23:116–120. doi: 10.1111/nep.13464
   PubMedGoogle Scholar
• Carriazo S, Villalvazo P, Ortiz A. More on the invisibility of chronic kidney disease … and counting. Clin Kidney J. 2022;15(3):388–392. doi: 10.1093/ckj/sfab240
   PubMed Web of Science ®Google Scholar
• Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the global burden of disease study 2017. The Lancet. 2020;395(10225):709–733. doi: 10.1016/S0140-6736(20)30045-3
   PubMed Web of Science ®Google Scholar
• Ruiz-Ortega M, Rayego-Mateos S, Lamas S, et al. Targeting the progression of chronic kidney disease. Nat Rev Nephrol. 2020;16(5):269–88. doi: 10.1038/s41581-019-0248-y
   PubMed Web of Science ®Google Scholar
• Qiu Y, Qiu Y, Yao G-M, et al. Natural product therapies in chronic kidney diseases: an update. Nephrol Ther. 2021;18(2):75–79. doi: 10.1016/j.nephro.2021.05.003
   PubMed Web of Science ®Google Scholar
• Li X, Wang H. Chinese herbal medicine in the treatment of chronic kidney disease. Adv Chronic Kidney Dis. 2005;12(3):276–81. doi: 10.1016/j.ackd.2005.03.007
   PubMed Web of Science ®Google Scholar
• Zhong Y, Menon MC, Deng Y, et al. Recent advances in traditional Chinese medicine for kidney disease. Am J Kidney Dis. 2015;66(3):513–22. doi: 10.1053/j.ajkd.2015.04.013
   PubMed Web of Science ®Google Scholar
• Xie Z, Liang A. New theoretical study on the biological origins of Chinese medicinal herbs. Zhongguo Zhong Yao Za Zhi. 1995;20(5):259–261.
   PubMedGoogle Scholar
• Hsieh C-F, Huang S-L, Chen C-L, et al. Increased risk of chronic kidney disease among users of non-prescribed Chinese herbal medicine in Taiwan. Prev Med. 2012;55(2):155–9. doi: 10.1016/j.ypmed.2012.06.003
   PubMed Web of Science ®Google Scholar
• Huang K-C, Su Y-C, Sun M-F, et al. Chinese herbal medicine improves the long-term survival rate of patients with chronic kidney disease in Taiwan: a nationwide retrospective population-based cohort study. Front Pharmacol. 2018;9:1117. doi: 10.3389/fphar.2018.01117
   PubMed Web of Science ®Google Scholar
• Lin M-Y, Chiu Y-W, Chang J-S, et al. Association of prescribed Chinese herbal medicine use with risk of end-stage renal disease in patients with chronic kidney disease. Kidney Int. 2015;88(6):1365–1373. doi: 10.1038/ki.2015.226
   PubMed Web of Science ®Google Scholar
• Zhang HW, Lin ZX, Tung YS, et al. Cordyceps sinensis (a traditional Chinese medicine) for treating chronic kidney disease. Cochrane Database Syst Rev. 2014;2014(12):CD008353. doi: 10.1002/14651858.CD008353.pub2
   PubMedGoogle Scholar
• Zhang HW, Lin ZX, Xu C, et al. Astragalus (a traditional Chinese medicine) for treating chronic kidney disease. Cochrane Database Syst Rev. 2014;2014(10):CD008369. doi:10.1002/14651858.CD008369.pub2
   PubMedGoogle Scholar
• Wang H, Song H, Yue J, et al. Rheum officinale (a traditional Chinese medicine) for chronic kidney disease. Cochrane Database Syst Rev. 2012;2012(7):CD008000. doi: 10.1002/14651858.CD008000.pub2
   Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928. doi: 10.1136/bmj.d5928
   PubMed Web of Science ®Google Scholar
• Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics. 2018;74(3):785–94. doi: 10.1111/biom.12817
   PubMed Web of Science ®Google Scholar
• Wang X-Q, Zou X-R, Yuan J, et al. Randomized controlled clinical study on treatment of Chinese herbs on stage 3 of chronic kidney disease. J Hubei Univer Chinese Med. 2011;13(5):15–18.
   Google Scholar
• Wang Y-J, He L-Q, Sun W, et al. Optimized project of traditional Chinese medicine in treating chronic kidney disease stage 3: a multicenter double-blinded randomized controlled trial. J Ethnopharmacol. 2012;139(3):757–764. doi: 10.1016/j.jep.2011.12.009
   PubMed Web of Science ®Google Scholar
• Fang Y-Q, Lu Y, Wang Y-J, et al. Efficiency of benazepril combined with wind dispelling and dampness removing Chinese herbs on stage 3 chronic kidney disease with wind-dampness syndrome: a prospective study. Chin J Integr Med Traditional And Western Medicine. 2012;32(3):311–316.
   Google Scholar
• Wang D, Wu T, Xie T, et al. Syndrome differentiation-based treatment with traditional Chinese medicine for proteinuria in patients with chronic kidney disease: a randomized multicenter trial. J Southern Med Univ. 2013;33(4):502–506.
   Google Scholar
• Wang Y-J, He L-Q, Sun W, et al. Clinical research of traditional Chinese medicine combined with renal protective effects of traditional Chinese medicine formula for patients with chronic kidney disease stage 3: a multi-center, prospective, double-blinded, randomized controlled trials of 315 cases. World Chinese Med. 2013;8(9):1001–1005.
   Google Scholar
• Ji W, Xi-Sheng X, Ming-Hua Z. Management of chronic kidney disease guided by the theory of traditional Chinese medicine: an experimental study. J Sichuan Univer. 2014;45(1):34–38.
   Google Scholar
• Yang T-H, Chen H-Y, Yang S-H, et al. Utilization pattern for traditional Chinese medicine among late stage chronic kidney disease patients: a hospital-based cross-sectional study. J Chinese Med. 2014;25(1):41–58.
   Google Scholar
• Gong X-Z, Zhou L-F, Wang Q, et al. Effect of chuanhuang No. 1 recipe on renal function and micro-inflammation in phase 3 chronic kidney disease patients. Chin J Integr Med Traditional And Western Medicine. 2015;35(2):137–141.
   Google Scholar
• Jinlian L, Tao L, Gen L. A study on relationship between the abnormal thyroid hormone and traditional Chinese medical syndrome in patients with chronic kidney disease. J Clin Nephrol. 2017;17(9):530–533.
   Google Scholar
• Yun C, Wenning F, Ying L. Clinical study on traditional Chinese medicine in the treatment of patients with chronic kidney disease in phase 5 (non-dialysis). World Chinese Med. 2018;13(6):1337–1341.
   Google Scholar
• Zhao J, Sun W, Chen J, et al. Efficacy and safety of Chinese herbal formula granules in treating chronic kidney disease stage 3: a multicenter, randomized, placebo-controlled, double-blind clinical trial. Evid Based Complement Alternat Med. 2020;2020:4073901. doi: 10.1155/2020/4073901
   PubMedGoogle Scholar
• Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ. 1997;315(7121):1533–7. doi: 10.1136/bmj.315.7121.1533
   PubMed Web of Science ®Google Scholar
• Shao M, Ye C, Bayliss G, et al. New insights into the effects of individual Chinese herbal medicines on chronic kidney disease. Front Pharmacol. 2021;12:774414. doi: 10.3389/fphar.2021.774414
   PubMed Web of Science ®Google Scholar
• Xia P, Gao K, Xie J, et al. Data mining-based analysis of Chinese medicinal herb formulae in chronic kidney disease treatment. Evid Based Complement Alternat Med. 2020;2020:9719872. doi: 10.1155/2020/9719872
   PubMed Web of Science ®Google Scholar
• Lang R, Wang X, Liang Y, et al. Research progress in the treatment of idiopathic membranous nephropathy using traditional Chinese medicine. J Transl Int Med. 2020;8(1):3–8. doi: 10.2478/jtim-2020-0002
   PubMed Web of Science ®Google Scholar
• Zhao M, Yu Y, Wang R, et al. Mechanisms and efficacy of Chinese herbal medicines in chronic kidney disease. Front Pharmacol. 2021;11:619201. doi: 10.3389/fphar.2020.619201
   PubMed Web of Science ®Google Scholar
• Qin Q, Niu J, Wang Z, et al. Astragalus membranaceus inhibits inflammation via phospho-P38 mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-κB pathways in advanced glycation end product-stimulated macrophages. Int J Mol Sci. 2012;13(7):8379–87. doi: 10.3390/ijms13078379
   PubMed Web of Science ®Google Scholar
• Cao Y, Ruan Y, Shen T, et al. Astragalus polysaccharide suppresses doxorubicin-induced cardiotoxicity by regulating the PI3k/Akt and p38MAPK pathways. Oxid Med Cell Longev. 2014;2014:674219. doi: 10.1155/2014/674219
   PubMed Web of Science ®Google Scholar
• Huang W, Li L, Tian X, et al. Astragalus and Paeoniae radix rubra extract inhibits liver fibrosis by modulating the transforming growth factorβ/Smad pathway in rats. Mol Med Rep. 2015;11(2):805–814. doi: 10.3892/mmr.2014.2868
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang L, He W, et al. Astragalus membranaceus inhibits peritoneal fibrosis via monocyte chemoattractant protein (MCP)-1 and the transforming growth factor-β1 (TGF-β1) pathway in rats submitted to peritoneal dialysis. Int J Mol Sci. 2014;15(7):12959–71. doi: 10.3390/ijms150712959
   PubMed Web of Science ®Google Scholar
• Cao Y, Huang X, Fan Y, et al. Protective effect of triptolide against glomerular mesangial cell proliferation and glomerular fibrosis in rats involves the TGF- β 1/Smad signaling pathway. Evid Based Complement Alternat Med. 2015;2015:814089. doi: 10.1155/2015/814089
   PubMed Web of Science ®Google Scholar
• Li J, Gong X. Tetramethylpyrazine: an active ingredient of Chinese herbal medicine with therapeutic potential in acute kidney injury and renal fibrosis. Front Pharmacol. 2022;13:820071. doi: 10.3389/fphar.2022.820071
   PubMed Web of Science ®Google Scholar
• Xie Y, Lan F, Zhao J, et al. Hirudin improves renal interstitial fibrosis by reducing renal tubule injury and inflammation in unilateral ureteral obstruction (UUO) mice. Int Immunopharmacol. 2020;81:106249. doi: 10.1016/j.intimp.2020.106249
   PubMed Web of Science ®Google Scholar
• Jia Q, Han L, Zhang X, et al. Tongluo yishen decoction ameliorates renal fibrosis via regulating mitochondrial dysfunction induced by oxidative stress in unilateral ureteral obstruction rats. Front Pharmacol. 2021;12:762756. doi: 10.3389/fphar.2021.762756
   PubMed Web of Science ®Google Scholar
• Wang YN, Liu HJ, Ren LL, et al. Shenkang injection improves chronic kidney disease by inhibiting multiple renin-angiotensin system genes by blocking the Wnt/β-catenin signalling pathway. Front Pharmacol. 2022;13:964370. doi: 10.3389/fphar.2022.964370
   PubMed Web of Science ®Google Scholar
• Zhang XW, Liu XX, Yong J, et al. Association of anti-phospholipase A2 receptor antibody with the efficacy of traditional Chinese medicine (shenqi particle) for patients with idiopathic membranous nephropathy: a prospective, cohort clinical study. Chinese Med J. 2021;134(18):2252–2254. doi: 10.1097/CM9.0000000000001565
   PubMed Web of Science ®Google Scholar
• Ma SX, Li XJ, Duan TT, et al. Moshen granule ameliorates membranous nephropathy by regulating NF-ƙB/Nrf2 pathways via aryl hydrocarbon receptor signalling. Heliyon. 2023;9(9):e20019. doi: 10.1016/j.heliyon.2023.e20019
   PubMed Web of Science ®Google Scholar
• Xiao YZ, Ye ZZ, Liang YT, et al. Association between Chinese herbal medicine therapy and the risk of chronic kidney disease in gout patients. Front Pharmacol. 2021;12:661282. doi: 10.3389/fphar.2021.661282
   PubMed Web of Science ®Google Scholar
• Cao W, Liu L, Peng J, et al. Effects of shenkang decoction on creatinine and blood urea nitrogen in chronic renal failure hemodialysis patients: a randomized controlled trial. J Integ complement med. 2023;29(4):253–60. doi: 10.1089/jicm.2022.0587
   PubMedGoogle Scholar
• Liu XY, Zhang XB, Zhao YF, et al. Research progress of Chinese herbal medicine intervention in renal interstitial fibrosis. Front Pharmacol. 2022;13:900491. doi: 10.3389/fphar.2022.900491
   PubMed Web of Science ®Google Scholar
• Zhong Y, Deng Y, Chen Y, et al. Therapeutic use of traditional Chinese herbal medications for chronic kidney diseases. Kidney Int. 2013;84(6):1108–18. doi: 10.1038/ki.2013.276
   PubMed Web of Science ®Google Scholar